Volume 20, Number 2—February 2014
Research
Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
Table
Characteristic | 12 mo |
24 mo |
|||||
---|---|---|---|---|---|---|---|
PCV-7, n = 97 | Control, n = 103 | p value | PCV-7, n = 97 | Control, n = 103 | p value | ||
Male sex |
54 (56) |
53 (51) |
NS |
54 (56) |
53 (51) |
NS |
|
Crowding | |||||||
Presence of siblings in household | 52 (54) | 57 (55) | NS | 64 (66) | 65 (63) | NS | |
Daycare attendance† |
62 (64) |
68 (66) |
NS |
75 (77) |
74 (72) |
NS |
|
Symptoms of UTRI | |||||||
UTRI (<6 mo) | 56 (58) | 55 (54) | NS | 41 (42) | 43 (42) | NS | |
Current cold‡ | 40 (41) | 38 (37) | NS | 36 (37) | 39 (38) | NS | |
Current otitis media | 3 (3) | 6 (6) | NS | 0 | 0 | NS | |
History of wheezing |
15 (16) |
13 (13) |
NS |
10 (10) |
9 (9) |
NS |
|
Smoke exposure at home | 6 (6) | 7 (7) | NS | 6 (6) | 6 (6) | NS | |
Antimicrobial drug use (<1 mo)§ |
4 (4) |
5 (5) |
NS |
2 (2) |
2 (2) |
NS |
|
Carriage detected by culture | |||||||
Streptococcus pneumoniae | 63 (64.9) | 80 (77.7) | 0.06 | 59 (60.8) | 75 (72.8) | 0.10 | |
Vaccine serotypes | 30 (30.9) | 51 (49.5) | 0.01 | 16 (16.5) | 42 (40.8) | 0.001 | |
Nonvaccine serotypes | 33 (34.0) | 29 (28.2) | NS | 43 (44.3) | 33 (32.0) | 0.08 | |
Moraxella catarrhalis | 75 (77.3) | 85 (82.5) | NS | 67 (96.1) | 81 (78.6) | NS | |
Haemophilus influenzae | 56 (57.7) | 50 (48.5) | NS | 55 (53.4) | 59 (57.3) | NS | |
Staphylococcus aureus | 9 (9.3) | 5 (4.9) | NS | 7 (6.8) | 4 (3.9) | NS |
*Values are no. (%) unless otherwise indicated. p values were calculated by using the χ2 test and are shown when there was a trend (p = 0.05–0.1) or a significant difference (p<0.05). PCV-7, 7-valent pneumococcal conjugate vaccine; NS, not significant (p>0.1); UTRI, upper respiratory tract infection.
†Defined as at least 4 h/wk of daycare with >1 child from a different family.
‡Presence of mild symptoms of a respiratory tract infection at time of sampling as reported by parents.
§Defined as use of antimicrobial drug within 1 mo before sampling.
1These authors contributed equally to this article.
2Deceased.
Page created: January 17, 2014
Page updated: January 17, 2014
Page reviewed: January 17, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.